Literature DB >> 9393972

A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis.

H Nishimori1, T Shiratsuchi, T Urano, Y Kimura, K Kiyono, K Tatsumi, S Yoshida, M Ono, M Kuwano, Y Nakamura, T Tokino.   

Abstract

The genetic alteration of p53 is associated with neovascularization during progression of glioma to its more malignant form, glioblastoma. Hence, one or more of the genes transactivated by p53 is likely to function as an angiogenesis inhibitors. We isolated a novel p53-inducible gene that encodes a 1584-amino-acid product containing five thrombospondin type 1 (TSP-type 1) repeats and is specifically expressed in the brain. A recombinant protein corresponding to the TSP-type 1 repeats of this gene product inhibited in vivo neovascularization induced by bFGF in the rat cornea. The expression of this gene, designated BAI1 (brain-specific angiogenesis inhibitor 1) was absent or significantly reduced in eight of nine glioblastoma cell lines, suggesting BAI1 plays a significant role in angiogenesis inhibition, as a mediator of p53.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393972     DOI: 10.1038/sj.onc.1201542

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  87 in total

1.  Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras.

Authors:  S M Nielsen; L Z Nielsen; S A Hjorth; M H Perrin; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

2.  Defective p53 antiangiogenic signaling in glioblastoma.

Authors:  Benjamin Berger; David Capper; Dieter Lemke; Philipp-Niclas Pfenning; Michael Platten; Michael Weller; Andreas von Deimling; Wolfgang Wick; Markus Weiler
Journal:  Neuro Oncol       Date:  2010-05-26       Impact factor: 12.300

3.  GPR56 plays varying roles in endogenous cancer progression.

Authors:  Lei Xu; Shahinoor Begum; Marc Barry; Denise Crowley; Liquan Yang; Roderick T Bronson; Richard O Hynes
Journal:  Clin Exp Metastasis       Date:  2010-03-24       Impact factor: 5.150

4.  Functional variability of Rev response element in HIV-1 primary isolates.

Authors:  Angsana Phuphuakrat; Prasert Auewarakul
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

5.  Gpr110 deficiency decelerates carcinogen-induced hepatocarcinogenesis via activation of the IL-6/STAT3 pathway.

Authors:  Benting Ma; Junjie Zhu; Juan Tan; Yulei Mao; Lingyun Tang; Chunling Shen; Hongxing Zhang; Ying Kuang; Jian Fei; Xiao Yang; Zhugang Wang
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

6.  A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.

Authors:  Daniel Menendez; Oliver Krysiak; Alberto Inga; Bianca Krysiak; Michael A Resnick; Gilbert Schönfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

7.  Splicing variants of the orphan G-protein-coupled receptor GPR56 regulate the activity of transcription factors associated with tumorigenesis.

Authors:  Jeong-Eun Kim; Ji Man Han; Cho Rong Park; Kum-Joo Shin; Curie Ahn; Jae Young Seong; Jong-Ik Hwang
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

8.  Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

Authors:  Balveen Kaur; Sarah M Cork; Eric M Sandberg; Narra S Devi; Zhaobin Zhang; Philip A Klenotic; Maria Febbraio; Hyunsuk Shim; Hui Mao; Carol Tucker-Burden; Roy L Silverstein; Daniel J Brat; Jeffrey J Olson; Erwin G Van Meir
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 9.  Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Authors:  NaTosha N Gatson; E Antonio Chiocca; Balveen Kaur
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

Review 10.  Versatile functions of p53 protein in multicellular organisms.

Authors:  P M Chumakov
Journal:  Biochemistry (Mosc)       Date:  2007-12       Impact factor: 2.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.